Sudeep Pharma Ltd. (SUDEEPPHRM.NS) Stock Competitors & Peer Comparison

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SUNPHARMA.BO has a market cap of 4.5T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SUNPHARMA.BO trades at ₹1,867.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SUNPHARMA.BO's P/E ratio is 41.05. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUNPHARMA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SUNPHARMA.NS has a market cap of 4.5T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SUNPHARMA.NS trades at ₹1,868.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SUNPHARMA.NS's P/E ratio is 39.01. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUNPHARMA.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while DIVISLAB.NS trades at ₹6,747.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas DIVISLAB.NS's P/E ratio is 69.51. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DIVISLAB.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while DIVISLAB.BO trades at ₹6,743.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas DIVISLAB.BO's P/E ratio is 66.65. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DIVISLAB.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while TORNTPHARM.BO trades at ₹4,514.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas TORNTPHARM.BO's P/E ratio is 71.37. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check TORNTPHARM.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while TORNTPHARM.NS trades at ₹4,514.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas TORNTPHARM.NS's P/E ratio is 70.82. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check TORNTPHARM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ZYDUSLIFE.BO trades at ₹1,112.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ZYDUSLIFE.BO's P/E ratio is 22.19. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ZYDUSLIFE.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ZYDUSLIFE.NS trades at ₹1,112.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ZYDUSLIFE.NS's P/E ratio is 22.20. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ZYDUSLIFE.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while DRREDDY.NS trades at ₹1,301.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas DRREDDY.NS's P/E ratio is 25.33. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DRREDDY.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while DRREDDY.BO trades at ₹1,301.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas DRREDDY.BO's P/E ratio is 19.18. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DRREDDY.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while LUPIN.NS trades at ₹2,357.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas LUPIN.NS's P/E ratio is 18.46. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LUPIN.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while LUPIN.BO trades at ₹2,356.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas LUPIN.BO's P/E ratio is 24.97. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LUPIN.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while MANKIND.BO trades at ₹2,529.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas MANKIND.BO's P/E ratio is 54.79. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check MANKIND.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while MANKIND.NS trades at ₹2,528.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas MANKIND.NS's P/E ratio is 54.73. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check MANKIND.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AUROPHARMA.BO has a market cap of 883.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AUROPHARMA.BO trades at ₹1,535.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AUROPHARMA.BO's P/E ratio is 26.07. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AUROPHARMA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AUROPHARMA.NS has a market cap of 882.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AUROPHARMA.NS trades at ₹1,534.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AUROPHARMA.NS's P/E ratio is 25.46. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AUROPHARMA.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, LAURUSLABS.NS has a market cap of 799.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while LAURUSLABS.NS trades at ₹1,481.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas LAURUSLABS.NS's P/E ratio is 90.36. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LAURUSLABS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, LAURUSLABS.BO has a market cap of 799.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while LAURUSLABS.BO trades at ₹1,480.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas LAURUSLABS.BO's P/E ratio is 90.35. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LAURUSLABS.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ALKEM.NS has a market cap of 647.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ALKEM.NS trades at ₹5,415.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ALKEM.NS's P/E ratio is 28.11. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALKEM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ALKEM.BO has a market cap of 646.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ALKEM.BO trades at ₹5,411.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ALKEM.BO's P/E ratio is 28.09. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALKEM.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GLENMARK.NS has a market cap of 615B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GLENMARK.NS trades at ₹2,179.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GLENMARK.NS's P/E ratio is 45.20. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLENMARK.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GLENMARK.BO has a market cap of 614.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GLENMARK.BO trades at ₹2,180.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GLENMARK.BO's P/E ratio is 45.27. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLENMARK.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVENPHAR.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, IPCALAB.NS has a market cap of 412.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while IPCALAB.NS trades at ₹1,625.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas IPCALAB.NS's P/E ratio is 36.08. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IPCALAB.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, IPCALAB.BO has a market cap of 412.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while IPCALAB.BO trades at ₹1,620.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas IPCALAB.BO's P/E ratio is 36.15. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IPCALAB.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVENPHAR.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AJANTPHARM.BO has a market cap of 399.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AJANTPHARM.BO trades at ₹3,188.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AJANTPHARM.BO's P/E ratio is 39.32. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AJANTPHARM.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AJANTPHARM.NS has a market cap of 398.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AJANTPHARM.NS trades at ₹3,187.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AJANTPHARM.NS's P/E ratio is 37.71. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AJANTPHARM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, JBCHEPHARM.NS has a market cap of 359.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while JBCHEPHARM.NS trades at ₹2,237.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas JBCHEPHARM.NS's P/E ratio is 50.24. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JBCHEPHARM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, JBCHEPHARM.BO has a market cap of 358.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while JBCHEPHARM.BO trades at ₹2,229.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas JBCHEPHARM.BO's P/E ratio is 50.29. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JBCHEPHARM.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, EMCURE.NS has a market cap of 344.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while EMCURE.NS trades at ₹1,816.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas EMCURE.NS's P/E ratio is 37.29. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check EMCURE.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, WOCKPHARMA.NS has a market cap of 326.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while WOCKPHARMA.NS trades at ₹2,010.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas WOCKPHARMA.NS's P/E ratio is 153.58. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check WOCKPHARMA.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, WOCKPHARMA.BO has a market cap of 326.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while WOCKPHARMA.BO trades at ₹2,010.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas WOCKPHARMA.BO's P/E ratio is 153.61. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check WOCKPHARMA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PEL.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, NEULANDLAB.BO has a market cap of 233.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while NEULANDLAB.BO trades at ₹18,040.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas NEULANDLAB.BO's P/E ratio is 63.71. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NEULANDLAB.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, NEULANDLAB.NS has a market cap of 232.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while NEULANDLAB.NS trades at ₹18,102.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas NEULANDLAB.NS's P/E ratio is 63.69. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NEULANDLAB.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, PPLPHARMA.NS has a market cap of 224.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while PPLPHARMA.NS trades at ₹168.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas PPLPHARMA.NS's P/E ratio is -68.65. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PPLPHARMA.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, PPLPHARMA.BO has a market cap of 224.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while PPLPHARMA.BO trades at ₹168.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas PPLPHARMA.BO's P/E ratio is -68.58. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PPLPHARMA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ASTRAZEN.BO has a market cap of 212.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ASTRAZEN.BO trades at ₹8,503.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ASTRAZEN.BO's P/E ratio is 113.65. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ASTRAZEN.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ASTRAZEN.NS has a market cap of 212.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ASTRAZEN.NS trades at ₹8,513.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ASTRAZEN.NS's P/E ratio is 113.42. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ASTRAZEN.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ERIS.NS has a market cap of 202.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ERIS.NS trades at ₹1,461.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ERIS.NS's P/E ratio is 32.29. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ERIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ERIS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ERIS.BO has a market cap of 202.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ERIS.BO trades at ₹1,459.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ERIS.BO's P/E ratio is 32.22. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ERIS.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GRANULES.NS has a market cap of 195.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GRANULES.NS trades at ₹788.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GRANULES.NS's P/E ratio is 32.20. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GRANULES.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GRANULES.BO has a market cap of 195.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GRANULES.BO trades at ₹787.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GRANULES.BO's P/E ratio is 35.00. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GRANULES.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, CAPLIPOINT.BO has a market cap of 189.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while CAPLIPOINT.BO trades at ₹2,492.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas CAPLIPOINT.BO's P/E ratio is 29.61. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check CAPLIPOINT.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, CAPLIPOINT.NS has a market cap of 189.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while CAPLIPOINT.NS trades at ₹2,490.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas CAPLIPOINT.NS's P/E ratio is 29.66. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check CAPLIPOINT.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, COHANCE.NS has a market cap of 175.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while COHANCE.NS trades at ₹457.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas COHANCE.NS's P/E ratio is 98.03. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check COHANCE.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, COHANCE.BO has a market cap of 174.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while COHANCE.BO trades at ₹458.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas COHANCE.BO's P/E ratio is 98.08. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check COHANCE.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, NATCOPHARM.NS has a market cap of 159.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while NATCOPHARM.NS trades at ₹892.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas NATCOPHARM.NS's P/E ratio is 11.27. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NATCOPHARM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, NATCOPHARM.BO has a market cap of 159.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while NATCOPHARM.BO trades at ₹892.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas NATCOPHARM.BO's P/E ratio is 10.39. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NATCOPHARM.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, JUBLPHARMA.NS has a market cap of 154B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while JUBLPHARMA.NS trades at ₹972.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas JUBLPHARMA.NS's P/E ratio is 38.81. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JUBLPHARMA.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, JUBLPHARMA.BO has a market cap of 154B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while JUBLPHARMA.BO trades at ₹973.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas JUBLPHARMA.BO's P/E ratio is 38.79. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JUBLPHARMA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, APLLTD.NS has a market cap of 152.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while APLLTD.NS trades at ₹777.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas APLLTD.NS's P/E ratio is 22.63. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check APLLTD.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, APLLTD.BO has a market cap of 152.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while APLLTD.BO trades at ₹776.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas APLLTD.BO's P/E ratio is 22.61. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check APLLTD.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ALIVUS.NS has a market cap of 137.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ALIVUS.NS trades at ₹1,118.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ALIVUS.NS's P/E ratio is 24.36. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALIVUS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ALIVUS.BO has a market cap of 137.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ALIVUS.BO trades at ₹1,118.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ALIVUS.BO's P/E ratio is 24.36. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALIVUS.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLS.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, VIYASH.NS has a market cap of 116.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while VIYASH.NS trades at ₹265.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas VIYASH.NS's P/E ratio is 66.47. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check VIYASH.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SHILPAMED.NS has a market cap of 115.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SHILPAMED.NS trades at ₹591.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SHILPAMED.NS's P/E ratio is 47.52. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SHILPAMED.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check CAPPL.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, PGHL.BO has a market cap of 103.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while PGHL.BO trades at ₹6,207.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas PGHL.BO's P/E ratio is 31.52. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PGHL.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, PGHL.NS has a market cap of 103B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while PGHL.NS trades at ₹6,203.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas PGHL.NS's P/E ratio is 31.54. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PGHL.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, STAR.NS has a market cap of 102.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while STAR.NS trades at ₹1,111.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas STAR.NS's P/E ratio is 18.40. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check STAR.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, STAR.BO has a market cap of 102.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while STAR.BO trades at ₹1,114.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas STAR.BO's P/E ratio is 18.45. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check STAR.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AKUMS.NS has a market cap of 94.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AKUMS.NS trades at ₹619.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AKUMS.NS's P/E ratio is 37.14. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AKUMS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SPARC.BO has a market cap of 76.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SPARC.BO trades at ₹235.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SPARC.BO's P/E ratio is 4.91. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SPARC.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SPARC.NS has a market cap of 76.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SPARC.NS trades at ₹234.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SPARC.NS's P/E ratio is 4.91. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SPARC.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, FDC.NS has a market cap of 67.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while FDC.NS trades at ₹412.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas FDC.NS's P/E ratio is 23.81. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check FDC.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, FDC.BO has a market cap of 67.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while FDC.BO trades at ₹411.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas FDC.BO's P/E ratio is 23.81. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check FDC.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AARTIPHARM.NS has a market cap of 64.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AARTIPHARM.NS trades at ₹710.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AARTIPHARM.NS's P/E ratio is 36.90. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIPHARM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AARTIPHARM.BO has a market cap of 64.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AARTIPHARM.BO trades at ₹711.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AARTIPHARM.BO's P/E ratio is 34.32. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIPHARM.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SUVEN.BO has a market cap of 57.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SUVEN.BO trades at ₹258.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SUVEN.BO's P/E ratio is -21.02. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVEN.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SUVEN.NS has a market cap of 57.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SUVEN.NS trades at ₹258.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SUVEN.NS's P/E ratio is -21.31. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVEN.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SHILPAMED.BO has a market cap of 57.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SHILPAMED.BO trades at ₹590.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SHILPAMED.BO's P/E ratio is 47.43. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SHILPAMED.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, INNOVACAP.NS has a market cap of 54B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while INNOVACAP.NS trades at ₹943.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas INNOVACAP.NS's P/E ratio is 38.37. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check INNOVACAP.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SEQUENT.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SEQUENT.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ORCHPHARMA.NS has a market cap of 50.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ORCHPHARMA.NS trades at ₹989.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ORCHPHARMA.NS's P/E ratio is 159.62. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ORCHPHARMA.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, ORCHPHARMA.BO has a market cap of 50.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while ORCHPHARMA.BO trades at ₹988.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas ORCHPHARMA.BO's P/E ratio is 67.68. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ORCHPHARMA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, BLISSGVS.NS has a market cap of 49.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while BLISSGVS.NS trades at ₹470.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas BLISSGVS.NS's P/E ratio is 39.14. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check BLISSGVS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, BLISSGVS.BO has a market cap of 49.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while BLISSGVS.BO trades at ₹469.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas BLISSGVS.BO's P/E ratio is 39.05. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check BLISSGVS.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GUJTHEM.NS has a market cap of 43.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GUJTHEM.NS trades at ₹400.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GUJTHEM.NS's P/E ratio is 93.13. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GUJTHEM.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, IOLCP.NS has a market cap of 39.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while IOLCP.NS trades at ₹133.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas IOLCP.NS's P/E ratio is 28.37. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IOLCP.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, IOLCP.BO has a market cap of 39.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while IOLCP.BO trades at ₹132.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas IOLCP.BO's P/E ratio is 28.33. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IOLCP.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, RPGLIFE.NS has a market cap of 38.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while RPGLIFE.NS trades at ₹2,307.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas RPGLIFE.NS's P/E ratio is 33.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check RPGLIFE.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, RPGLIFE.BO has a market cap of 37.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while RPGLIFE.BO trades at ₹2,303.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas RPGLIFE.BO's P/E ratio is 33.13. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check RPGLIFE.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GUFICBIO.NS has a market cap of 37.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GUFICBIO.NS trades at ₹370.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GUFICBIO.NS's P/E ratio is 57.94. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GUFICBIO.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, GUFICBIO.BO has a market cap of 36.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while GUFICBIO.BO trades at ₹368.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas GUFICBIO.BO's P/E ratio is 57.54. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GUFICBIO.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, NOVARTIND.NS has a market cap of 36.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while NOVARTIND.NS trades at ₹1,472.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas NOVARTIND.NS's P/E ratio is 38.97. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NOVARTIND.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, NOVARTIND.BO has a market cap of 36.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while NOVARTIND.BO trades at ₹1,468.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas NOVARTIND.BO's P/E ratio is 38.88. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NOVARTIND.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AARTIDRUGS.NS has a market cap of 34.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AARTIDRUGS.NS trades at ₹375.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AARTIDRUGS.NS's P/E ratio is 17.56. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIDRUGS.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, AARTIDRUGS.BO has a market cap of 34.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while AARTIDRUGS.BO trades at ₹374.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas AARTIDRUGS.BO's P/E ratio is 17.55. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIDRUGS.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, UNICHEMLAB.NS has a market cap of 30.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while UNICHEMLAB.NS trades at ₹436.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas UNICHEMLAB.NS's P/E ratio is 12.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check UNICHEMLAB.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, UNICHEMLAB.BO has a market cap of 30.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while UNICHEMLAB.BO trades at ₹436.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas UNICHEMLAB.BO's P/E ratio is 12.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check UNICHEMLAB.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, MOREPENLAB.NS has a market cap of 28.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while MOREPENLAB.NS trades at ₹52.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas MOREPENLAB.NS's P/E ratio is 30.23. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check MOREPENLAB.NS's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, MOREPENLAB.BO has a market cap of 28.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while MOREPENLAB.BO trades at ₹52.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas MOREPENLAB.BO's P/E ratio is 29.22. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check MOREPENLAB.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SOLARA.BO has a market cap of 27.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SOLARA.BO trades at ₹578.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SOLARA.BO's P/E ratio is -342.57. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SOLARA.BO's competition here

SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDEEPPHRM.NS stands at 94.6B. In comparison, SOLARA.NS has a market cap of 27.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹837.80, while SOLARA.NS trades at ₹579.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDEEPPHRM.NS currently has a P/E ratio of 56.15, whereas SOLARA.NS's P/E ratio is -342.66. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SOLARA.NS's competition here